ARS Pharmaceuticals shares jumped Monday after the company inked a deal to commercialize its allergic reaction nasal spray internationally.

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak ...

ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions: Hørsholm, Denmark Tuesday, November 12, 2024, 12:00 Hrs [IST] ...

ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to commercialize ...

Commercial launch of neffy®(epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good day, and welcome to the ARS Pharmaceuticals Third Quarter ...

Under the latest deal, ARS is in line to receive up to $320 million in regulatory and sales milestones, plus tiered, double-digit royalties in the teens on net sales in places where ALK will market ...

Under the agreement, ARS Pharma is entitled to receive an upfront payment of USD 145 million (DKK 1 billion) from ALK. Furthermore, ARS Pharma may receive up to USD 320 million (DKK 2.2 billion ...

ALK’s CEO, Peter Halling, said: “We are excited about the deal with ARS Pharma. It is an important step in ALK’s strategic efforts to establish leading positions in anaphylaxis, food allergy ...

Under the agreement, ARS Pharma is entitled to receive an upfront payment of USD 145 million (DKK 1 billion) from ALK. Furthermore, ARS Pharma may receive up to USD 320 million (DKK 2.2 billion) ...

ALK’s CEO, Peter Halling, said: “We are excited about the deal with ARS Pharma. It is an important step in ALK’s strategic efforts to establish leading positions in anaphylaxis, food allergy, and new ...